External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease

This work was supported by National Institute of Health grants R01DA037648 (Philibert) and R44DA041014 (Philibert), and Cardio Diagnostics, Inc. On behalf of MV Dogan and R Philibert, the University of Iowa has filed intellectual property claims related to the integrated genetic-epigenetic technology described in this communication (US Patent application 62,455,416: Compositions and Methods for Detecting Predisposition to Cardiovascular Disease). On behalf of MV Dogan, R Philibert and TK Dogan, Cardio Diagnostics, Inc. has filed intellectual property claims related to the integrated genetic-epigenetic technology described in this communication (US Patent application 63,074,878: Methods and Compositions for Predicting Coronary Heart Disease). They are potential royalty recipients on these intellectual right claims. MV Dogan is the chief executive officer and stockholder of Cardio Diagnostics, Inc. R Philibert is the chief medical officer and stockholder of Cardio Diagnostics, Inc. TK Dogan is an employee and stockholder of Cardio Diagnostics, Inc. (www.cardiodiagnosticsinc.com). None of the other authors have any conflicts to disclose. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The National Institutes of Health had no role in the design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish the results. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

留言 (0)

沒有登入
gif